ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC). Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron. Top line interim results anticipated in third quarter of 2023. Oegstgeest, 30 November […]

NXI Therapeutics Press Release NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression 30 November 2022, Basel, Switzerland – NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune […]

Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue

STIMULAN® gives surgeons the freedom to choose and combine the antibiotics that support their infection treatment strategy Keele, UK, 29 November 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce that STIMULAN® has received a new […]

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has been dosed with STC-15, the Company’s first-in-class clinical candidate. Read more…

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Los Angeles, California, USA, November 22nd, 2022 – ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. (“TriSalus”), an oncology therapeutics company integrating immunotherapy with disruptive delivery […]